Back to results
US 12,767,716 B2Granted
Anti-PD-1 antibodies and methods of use
OwnerJuan Carlos Almagro, Sonia Mayra Perez-Tapiainventors
Life of this patent
Estimating the term…
Abstract
Provided herein are binding molecules that bind to programmed cell death protein 1 (PD-1). Such binding molecules block the interaction between PD-1 and programmed death-ligand 1 and 2 (PD-L1 and PD-L2). Also provided herein are methods of using such binding molecules for preventing and treating cancer.
Claims19
A binding molecule that binds to programmed cell death protein 1 PD-1), wherein the binding molecule comprises:
- a) a variable heavy chain CDR1 (HCDR1) comprising an amino acid sequence of SEQ ID NO:
- 1;
- b) a variable heavy chain CDR2 (HCDR2) comprising an amino acid sequence of SEQ ID NO:
- 2;
- c) a variable heavy chain CDR3 (HCDR3) comprising an amino acid sequence of SEQ ID NO:
- 3;
- d) a variable light chain CDR1 (LCDR1) comprising an amino acid sequence of SEQ ID NO:
- 4;
- e) a variable light chain CDR2 (LCDR2) comprising an amino acid sequence of SEQ ID NO:
- 5;
- and
- f) a variable light chain CDR3 (LCDR3) comprising an amino acid sequence of SEQ ID NO:
- 6,
- wherein the binding molecule is numbered with reference to Kabat numbering system.
11 more elements
Dependencies are inferred from the claim text.